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Abstract
Background: Strongyloidiasis is a parasitic disease widely present in tropical and subtropical areas. Strongyloides
stercoralis represents the main species that infects human beings. Ivermectin is the current drug of choice;
however, issues related with treatment failure in patients with diabetes or infected with T-lymphotropic virus-1
make the identification of new molecules for alternative treatment a priority. In the present study, the activity of
sphingosine-related aminoalcohol and diamine were evaluated against Strongyloides venezuelensis third-stage
larva (L3) cultures and experimental infections in mice.
Methods: The efficacy of each compound against L3 was assessed using both XTT (2,3-bis-(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay and microscopic observation with concentrations ranging from
1 to 350 μM. Cytotoxicity was evaluated using J774.2 macrophage cell line and XTT assay. Lethal concentration 50
(LC50), selectivity index (SI) and structure-activity relationships were established. The activity compounds 4 (2-(ethylamino)
hexadecan-1-ol), 6 (2-(butylamino) hexadecan-1-ol), 17 (tert-butyl N-(1-aminododecan-2-yl) carbamate) and 18 (tert-butyl
N-(1-aminohexadecan-2-yl) carbamate) were further assessed against experimental S. venezuelensis infections in CD1 mice
measuring reductions in the numbers of parthenogenetic females and egg passed in faeces. Mice were infected with
3,000 L3 and treated with 20 mg/kg/day for five days.
Results: In the screening study of 15 aminoalcohols [lauryl (n = 9); palmityl (n = 13); stearyl (n = 15) and alcohol
derivatives], the presence of a palmitol chain was associated with the highest efficacy against L3 (LC50 31.9–39.
1 μM). Alkylation of the 2-amino group with medium size fragments as ethyl or n-butyl showed the best larvicidal
activity. The dialkylation did not improve efficacy. Aminoalcohols 4 and 6 showed the highest SI (1.5 and 1.6,
respectively). With respect to diamine derivative compounds, a chain size of sixteen carbon atoms (palmitoyl chain,
n = 13), and the alkylation of the 2-amino group with medium-sized fragments, were associated with the highest lethal
activities. The presence of carbamoyl group in diamines 17 and 18 yielded high SI (1.7 and 1.4, respectively). Infected
mice treated with aminoalcohol 6 showed reduction in parthenogenetic females (59 %) and eggs in faeces (51 %).
Conclusions: These results support the potentiality of aminoalcohol and diamine sphingosine-related compounds as
suitable prototypes for developing new promising drugs against strongyloidiasis.
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Background
Strongyloidiasis is a parasitic disease caused by nematodes
of the genus Strongyloides, which are widely present in
tropical and subtropical areas with climate suitable for the
survival of larval stages of the species of this genus. The
main species causing the disease in the human beings is
Strongyloides stercoralis and it is estimated that 30 to 100
million people are infected around the world [1]. Strong-
yloidiasis is also classified as a Neglected Tropical Disease,
according to the World Health Organization [2, 3]. This
parasite has a complex life-cycle: larvae penetrate the skin
of the host and migrate through the bloodstream to the
lungs, where they enter into the alveolar spaces, ascending
to the respiratory tree, the trachea, the pharynx and finally
migrate back through the oesophagus and stomach into
the intestine where they reach maturity [4–6]. Partheno-
genetic females inhabit the mucosa of the small intestine
where the eggs are laid. The rhabditiform larvae (L1) are
eliminated together with faeces and develop over a few
days in temperate and humid environment to infective
third-stage filariform larvae (L3). Minimally symptomatic
chronic infection and cutaneous, respiratory or gastro-
intestinal signs are observed in patients. Strongyloides ster-
coralis has also the ability to cause systemic disseminated
infection and hyperinfection syndrome in immunocom-
promised humans. In most of these cases the outcome of
the disease is fatal [7, 8].
Ivermectin is an effective well-tolerated drug against
strongyloidiasis, reaching cure rates of 93.1–96.8 % with
one single dose administration [9]. On the other hand,
treatment failure has been observed in patients co-
infected with S. stercoralis and human T-lymphotropic
virus-1 (HTLV-1) [10] and concomitancy with diabetes
[11]. Albendazole, mebendazole and thiabendazole given
in multiple doses are also used for the treatment of
strongyloidiasis but their efficacy and tolerability is not
as efficient as ivermectin [12, 13]. The concern about
decreased efficacy in human nematodosis and the possi-
bility of acquired-resistance in treatments of human
nematodes is increasing [14, 15]. Additionally, rare
population genotypes have shown encephalopathy when
treated against Loa loa infections with ivermectin [16]
making the discovery of new alternative nematicidal
drugs a high priority challenge.
Long chain aminoalcohols and diamine derivatives are
sphingosine-related compounds considered as key mole-
cules for designing alternative drugs to the current treat-
ment of infectious diseases. Biocidal activity of these
compounds has been reported against bacteria such as
Mycobacterium tuberculosis [17], protozoans such as Plas-
modium spp. [18] Leishmania spp. [19], Trypanosoma bru-
cei [20], T. cruzi [21], Trichomonas vaginalis, Giardia
lamblia [22], fungi [23] and helminths such as Schistosoma
mansoni [24] or the nematode Caenorhabditis elegans [25].
Alkylphospholipids are molecules structurally related to
long-chain aminoalcohols and diamines with promising
anticancer, antiprotozoal and anthelminthic activity. Their
activity is exerted through the interaction with cell mem-
branes, activating apoptosis [26].
In the present study, we have synthesized and evaluated
the anti-Strongyloides activity of two series of sphingosine
derivative compounds including aminoalcohol and diamine
derivatives. We have studied their effect on cultures of
third-stage S. venezuelensis larvae, and those compounds
showing good activity were selected to assess their efficacy
against S. venezuelensis in experimental infections in mice.
We also studied cytotoxicity and structure-activity relation-
ships of these aminoalchol and diamine derivatives.
Methods
Animals and ethics statement
Animal procedures complied with the European Union
(Di 2010/63/CE) and the Spanish (L32/2007, L6/2013,
RD53/2013) regulations on animal experimentation. The
University of Salamanca’s Ethics Committee also ap-
proved the procedures that were used in this study
(Protocol: 48531). Male Wistar rats weighing 80–120 g
from the Animal Experimentation facilities of the Uni-
versity of Salamanca (Registration No. PAE/SA/001) and
male Specific Pathogen Free (SPF) CD1 mice (Charles
River, Barcelona, Spain) weighing 25–30 g were used for
the maintenance of S. venezuelensis life-cycle and for in
vivo experiments in standard conditions. Size of groups
was calculated by power analysis [27] using “size.fdr” pack-
age for R and following the 3Rs recommendations [28].
Maintaining Strongyloides venezuelensis life-cycle and
parasitological techniques
The S. venezuelensis strain from the Department of Para-
sitology (University of Minas Gerais, Belo Horizonte,
Brazil) was maintained at the University of Salamanca
(biosecurity protocol No. 15/019) by serial in vivo pas-
sages in Wistar rats. The infective third-stage larvae
(L3) of S. venezuelensis were obtained from 3 to 4 day-
old vermiculite cultures of faeces from infected rats
using a Baermann apparatus. L3 were decontaminated
according to the methodology previously reported by
Martins et al. [29]. Freshly obtained L3 were washed six
times, for twenty minutes each, with distilled water con-
taining 100 IU/ml penicillin, 0.1 mg/ml streptomycin and
0.8 mg/ml fluconazole. Absence of bacterial contamin-
ation was confirmed by culturing larvae from each batch
on a Petri dish containing blood agar at 28 °C during 24 h.
Wistar rats were infected with 6,000 L3 in 0.5 ml phos-
phate buffered saline (PBS) using a 23-gauge needle syr-
inge to maintain the life-cycle. To perform faecal egg
counts, mice were placed on grids over clean moist
absorbent paper and allowed to defecate. Individual faecal
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samples were collected, conserved in a 10 % v/v formalin
buffered solution and counted in triplicate under a micro-
scope using McMaster technique and egg per gram were
reported. The upper half of the small intestine was re-
moved after euthanasia (pentobarbital 100 mg/kg), minced
and placed in a sedimentation cup wrapped by 8 layers of
gauze in PBS for 2 h at 37 °C. The parthenogenetic
females were then collected from the sediment and their
number recorded.
Drugs and sample preparation
The procedures for the synthesis of 2-aminoalkan-1-ol
(type I; compounds 1–15) and alkane 1,2-diamine (type
II; compounds 16–25) derivatives, which are structurally
related to sphingosine, were previously reported (Fig. 1)
[17, 19, 20, 30]. Fifteen aminoalcohol and ten diamine
derivatives were synthesized. Compounds were solubi-
lized in dimethyl sulfoxide (DMSO) and appropriate
dilutions were made to perform assays. Edelfosine (1-
O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine)
was obtained from R. Berchtold (Biochemisches Labor,
Bern, Switzerland) and used as reference for in vitro stud-
ies. Ivermectin was purchased from Sigma (St Louis, MO,
USA) and used as a reference drug for the in vivo treat-
ment of strongyloidiasis.
Cytotoxicity assessment in mouse macrophage cultures
The J774.2 mouse-derived peritoneal macrophage cell line
was used to assess the cytotoxicity of the compounds.
Macrophages were grown and serial successive in vitro
passages were performed according to the methodology
previously described by Rojas-Caraballo et al. [31]. To
study the cytotoxicity of each compound, 200 μl of a sus-
pension containing 1 × 105 cells/ml were added onto 96
well flat-bottom microplates, allowed to adhere to the sur-
face of the plate for 2 h at 37 °C, 5 % CO2 and then exposed
to the compounds for 72 h at the following concentrations:
0.1; 0.5; 3.3; 15.0; 35.0; and 70.0 μM. Each concentration
was assayed at least in triplicate in three independent
experiments. Cytotoxicity was evaluated based on the
colorimetric 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT) assay. After the treat-
ment, 50 μl of XTT solution were added to each individual
well and plates were incubated for 24 h at 37 °C. The ab-
sorbance of the plate was then measured at 492 nm using
an ELISA-plate reader (Anthos Labtec Instruments, Wals,
Austria). Results were expressed as the percentage of mac-
rophages remaining alive after each treatment. Untreated
and DMSO-treated macrophages were used as controls.
Each concentration was assayed in triplicate in three inde-
pendent experiments and the LC50 value for each com-
pound was calculated by sigmoidal regression analysis [32].
Efficacy and structure-activity study relationship of
compounds against third-stage larva cultures
A hundred decontaminated L3 in water were added to
96-well flat bottom microplates. Each compound was
added at 1, 10, 35, 70 and 350 μM and then incubated
during 72 h at 28 °C in triplicate and in a minimum of
three independent experiments. Larval viability was quan-
tified both by using the colorimetric XTT assay as de-
scribed above and by monitoring larval motility at 24, 48
and 72 h post-treatment. Larval movement was recorded
after stimulation with direct natural light for 2 min using
an inverted microscope (CK2, Olympus, Tokio, Japan) and
a video recorder (AM423 camera and DinoCapture 2.0
software, Dino-Lite digital microscope, Naarden, Holland).
Larvae were considered dead when no movement was de-
tected for at least two minutes of detailed examination. As
controls, L3 were incubated in water or treated with edel-
fosine in a range of 1–350 μM. Results were expressed as
the concentration of each compound able to inhibit 50 %
of total larvae movement (LC50), calculated by sigmoidal
regression analysis [32]. Selectivity Index (SI) was calcu-
lated as the ratio between the LC50 value of each com-
pound in macrophage culture and the LC50 in L3 cultures
to compare the efficacy and toxicity of each compound.
Potency relative to edelfosine (PEDEL) was calculated as
the ratio between edelfosine-LC50 and LC50 of each com-
pound. Edelfosine, a sphingosine-related compound, was
used based on the low toxicity and high in vitro activity
against helminths observed in previous experiments in
our laboratory [33] The influence of the side-chain size,
the substitution of the 2-amino group, and the presence of
a free hydroxyl function or a benzyl ether on the activity
of each compound were studied in compounds of type I.
Fig. 1 General structures for aminoalcohol derivatives (type I, compounds 1–15) and diamine derivatives (type II, compounds 16–25)
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The influence of the substituents on the 1-amino group
and the presence of a tert-butoxycarbonyl (Boc) protecting
group on the 2-amino group have also been examined in
type II compounds.
Assessment of efficacy against S. venezuelensis infection
in mice
Those compounds showing the best activity against L3
in the screening test (aminoalcohols 4 and 6, and di-
amines 17 and 18) were tested in S. venezuelensis experi-
mental infections of mice. For this purpose, we used a
total of 64 male CD1 mice randomly distributed in
groups of eight animals. We performed two independent
experiments with four groups each: infection control,
infected and treated with ivermectin and two groups
infected and treated with their respective selected com-
pound. In the first experiment, the aminoalcohols 4 and
6 were tested and in the second experiment the di-
amines 17 and 18 were tested. All mice were subcutane-
ously infected with 3,000 L3 of S. venezuelensis prior to
drug treatment. Ivermectin was orally administered with
a single standard dose of 0.2 mg/kg on day 5 post-
infection (p.i.). Aminoalcohols and diamines were orally
administered with a dose of 20 mg/kg/day at the day of
infection and during the next five days to let reaching
therapeutical concentration after day 5 p.i. Doses were
determined on the basis of the cytotoxicity and previous
experience in our laboratory with using sphingosine-
related compounds [23, 34]. The number of parasitic
females in the gut on day 7 p.i. and the number of eggs
released in the faeces during the experiment were quan-
tified to evaluate the efficacy of the treatment.
Statistical analysis
The results were expressed as the mean and the standard
error of the mean (SEM). Normality of data distribution
was assessed by the non-parametric Kolmogorov-Smirnov
test and the homogeneity of variance was tested by the
Barrett test. Significant differences between groups were
found using one-way ANOVA followed by Tukey’s honest
significance test. All statistical analyses were considered
significant at a P-value < 0.05. All analyses and graphics
were performed with Prism 5 (GraphPad Software, San
Diego, CA) for Mac.
Results
Efficacy of aminoalcohols and diamines against S.
venezuelensis L3
Concerning the in vitro activity against S. venezuelensis
larvae of the aminoalcohol derivatives (compounds 1–15
in Table 1), compounds 4 and 6 showed the highest
larvicidal activity (LC50 = 35.1 ± 0.1 and 31.9 ± 0.5 μM,
respectively), that is 1.4 and 1.5 times, respectively, more
potent than edelfosine (LC50 = 49.6 ± 0.5 μM) but less
than ivermectin (LC50 = 0.46 ± 0.1 μM) after 72 h of
culture. Compounds 4 and 6 had cytotoxicity values of
LC50 = 52.0 ± 5.3 μM and LC50 = 52.0 ± 4.1 μM, respec-
tively, which were also less toxic than edelfosine or iver-
mectin for macrophages (LC50 = 40.7 ± 7.1 and 1.1 ±
0.1 μM, respectively). The SI for edelfosine and ivermec-
tin were 0.8 and 2.4, respectively, while for compounds
4 and 6 the SI were 1.5 and 1.6, respectively, meaning
double selectivity (Table 1; Additional file 1: Video S1,
Additional file 2: Video S2 and Additional file 3: Video
S3 for compound 4 and Additional file 4: Video S4,
Additional file 5: Video S5 and Additional file 6: Video
S6 for compound 6). Compounds 14, 9, 11 and 1 also
elicited good activity with SI values ranging from 0.7 to
0.5 compared to edelfosine activity. Unfortunately all of
these were more toxic than edelfosine.
Ten alkane-1,2-diamines were also tested, compounds
16–25 (Table 2). Compounds 17, 18, 23 and 24 were
more potent than edelfosine, with relative potency values
of 1.2, 1.2, 1.2 and 1.4, respectively. Compounds 23 and
24 were more toxic than edelfosine, while SIs of com-
pounds 17 and 18 were 1.7 and 1.4, respectively (Table 2:
Additional file 7: Video S7, Additional file 8: Video S8
and Additional file 9: Video S9 for compound 17 and
Additional file 10: Video S10, Additional file 11: Video
S11 and Additional file 12: Video S12 for compound 18).
Compounds 25, 16, 20 and 22 have also shown good
activity, ranging from 0.7 to 0.5 compared to edelfosine
activity. Compound 16 cytotoxicity was similar to edelfo-
sine while the other three were more toxic.
Compounds, 4, 6, 17 and 18, which reached the highest
SI values, seemed to act in a dose- and time-dependent
manner, since larval viability was progressively inhibited
to completion as dose and time increased. As a conse-
quence of the global consideration of SI values, larval
viability measured by XTT and motility examination, the
four compounds were selected for evaluation of their in
vivo efficacy in infected mice.
Efficacy of aminoalcohols and diamines against S.
venezuelensis experimental infections in mice
The in vivo anti-Strongyloides efficacy of compounds 4,
6, 17 and 18 is summarized in Table 3 and Fig. 2. Ami-
noalcohol 6 induced parthenogenetic female burden re-
duction of 59 % (Fig. 2a) and significant reductions in
egg numbers in faeces on days 6 and 7 p.i. ranging from
35 to 51 %, respectively (Table 3) compared to infection
controls. Administration of diamine 18 resulted in re-
duction in the number of eggs in faeces on day 7 p.i
(50 %; Table 3) and moderate but not significant reduc-
tion of parthenogenetic females in the gut (25 %; Fig. 2b).
Despite aminoalcohol 4 and diamine 17 inducing a
moderate reduction of eggs in faeces (45 and 21 %, re-
spectively) they failed to reduce female burdens on day 7
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Table 1 In vitro efficacy and selectivity measured by XTT of alkane aminoalcohol derivatives against S. venezuelensis third-stage larvae (L3)
Compound R1 R2 R3 n Efficacy against L3 PEDEL
a Cytotoxicity SIb
LC50 (μM) LC50 (μM)
Mean ± SEM Mean ± SEM
1 H H H 9 97.8 ± 10.6 0.5 17.4 ± 0.4 0.2
2 H H H 13 348.4 ± 1.5 0.1 nt –
3 H H H 15 239.3 ± 7.9 0.2 nt –
4 H H Et 13 35.1 ± 0.1c* 1.4 52.0 ± 5.3 1.5
5 H H Bu 9 297.6 ± 5.4 0.1 37.9 ± 1.9 0.1
6 H H Bu 13 31.9 ± 0.5d* 1.5 52.0 ± 4.1 1.6
7 H H Bu 15 293.3 ± 2.6 0.1 10.0 ± 1.5 < 0.1
8 H H Hex 9 122.7 ± 6.4 0.4 43.2 ± 0.9 0.4
9 H H Hex 13 84.2 ± 4.3 0.5 10.9 ± 1.3 0.1
10 H H Hex 15 112.5 ± 5.3 0.4 54.2 ± 0.9 0.5
11 H Et Et 13 90.0 ± 5.7 0.5 2.2 ± 2.2 <0.1
12 H Bu Bu 9 169.0 ± 9.2 0.2 63.7 ± 1.2 0.4
13 H Bu Bu 13 192.1 ± 7.7 0.2 nt –
14 Bn H H 13 67.6 ± 6.3 0.7 30.2 ± 0.3 0.4
15 Bn H Bu 13 232.0 ± 4.5 0.2 nt –
Edelfosine 49.6 ± 0.5 1.0 40.7 ± 7.1 0.8
Abbreviations: Bn Benzyl, Bu Butyl, Et Ethyl, nt not tested, SEM standard error of the mean, R1 substituent on the hydroxyl group; R2 and R3 substituents on the
amine group
aPotency relative to edelfosine (PEDL) = Compound-LC50 against L3 / Edelfosine-LC50 against L3
bSelectivity index (SI) = Compound-LC50 to macrophages/Compound-LC50
against L3
c*Significant increase in PEDEL compared to edelfosine (ANOVA F(15, 62) = 413.82, P < 0.001; HDS P = 0.008)
d*Significant increase in PEDEL compared to edelfosine (ANOVA F(15, 62) = 413.82, P < 0.001;
bHDS P = 0.002)
Table 2 In vitro efficacy and selectivity measured by XTT of alkane diamines derivatives against S. venezuelensis third-stage larvae (L3)
Compound R1 R2 R3 n Efficacy against L3 PEDEL
a Cytotoxicity SIb
LC50 (μM) LC50 (μM)
Mean ± SEM Mean ± SEM
16 H H H 13 75.0 ± 4.1 0.6 40.1 ± 0.4 0.5
17 H H Boc 9 39.0 ± 2.9c* 1.2 66.6 ± 2.2 1.7
18 H H Boc 13 39.1 ± 4.7c* 1.2 56.2 ± 3.3 1.4
19 H H Boc 15 45.7 ± 9.2 1.0 36.8 ± 2.8 0.8
20 H Et H 13 95.4 ± 1.5 0.5 10.5 ± 1.4 0.1
21 H Bu H 13 148.3 ± 3.3 0.3 15.5 ± 1.2 0.1
22 H Hex H 13 83.6 ± 3.1 0.5 5.2 ± 0.5 0.0
23 H Hex Boc 13 38.9 ± 4.6c* 1.2 4.9 ± 0.8 0.1
24 Et Et H 13 33.4 ± 0.7 d* 1.4 13.2 ± 1.7 0.3
25 Hex Hex Boc 13 67.8 ± 7.1 0.7 7.6 ± 0.6 0.1
Edelfosine 49.6 ± 0.5 1.0 40.7 ± 7.1 0.8
Abbreviations: Bn Benzyl, Bu butyl, Et ethyl, Hex hexyl, Boc, tert-butoxycarbonyl, SEM standard error of the mean; R1 and R2 substituents on the amine at position
C-1; R3 substituents on the amine at position C-2
aPotency relative to edelfosine (PEDL) = Compound-LC50 against L3 / Edelfosine-LC50 against L3
bSelectivity index (SI) = Compound-LC50 to macrophages/Compound-LC50 against L3
c*Significant increase in PEDEL compared to edelfosine ANOVA: F(10, 72) = 216.85, P < 0.001; HDS P = 0.001
c*Significant increase in PEDEL compared to edelfosine ANOVA: F(10, 72) = 216.85, P < 0.001; HDS P < 0.001
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Table 3 Reduction in egg per gram of faeces (EPGF) in mice infected with 3,000 S. venezuelensis L3 after treatment with aminoalcohol
derivatives 4 and 6 and diamine derivatives 17 and 18 for five days at a dose of 20 mg/kg, and ivermectin 0.2 mg/kg
Groups EPGF on day 5 EPGF on day 6 HDS EPGF on day 7 HDS
(Mean ± SEM) Reduction (%) (Mean ± SEM) Reduction (%) P (Mean ± SEM) Reduction (%) P
Experiment 1
Infected 2,020 ± 430 – 24,800 ± 5,210 – 12,5150 ± 9,200 –
Ivermectin 5,240 ± 580 nr 330 ± 110 99a <0.001 0 ± 0 100a < 0.001
Aminoalcohol 4 3,830 ± 570 nr 20,220 ± 3,080 18 0.274 68,980 ± 12,810 45a < 0.001
Aminoalcohol 6 4,720 ± 900 nr 16,160 ± 1970 35a 0.044 61,680 ± 1,917 51a < 0.001
ANOVA F(3, 28) = 3.28;
P = 0.051
F(3, 28) = 13.42;
P < 0.001
F(3, 28) = 45.31;
P < 0.001
Experiment 2
Infected 3,190 ± 300 – 11,060 ± 1,710 – 82,820 ± 5,364 –
Ivermectin 2,950 ± 300 8 160 ± 90 99a <0.001 80 ± 50 100a < 0.001
Diamine 17 2,715 ± 410 15 10,890 ± 1,200 2 0.912 65,520 ± 7,037 21a 0.025
Diamine 18 3,410 ± 520 nr 8,110 ± 430 27 0.060 41,450 ± 5,382 50a < 0.001
ANOVA F(3, 28) = 0.59;
P = 0.625
F(3, 28) = 23.03;
P < 0.001
F(3, 28) = 47.94;
P < 0.001
Abbreviations: HDS Tukey’s honest significance test, nr no reduction, SEM standard error of the mean
aSignificant reduction compared to infected control group
Fig. 2 Number of parthenogenetic females on day 7 post-infection. a Mice treated with 20 mg/kg of aminoalcohols 4 and 6 (ANOVA F(2, 28) = 62.93,
P < 0.001). b Mice treated with 20 mg/kg of diamines 17 and 18 (ANOVA F(3, 28) = 48.03, P < 0.001). Worms were recovered from the intestine of mice
infected with 3,000 S. venezuelensis L3 and treated during five days. Each point represents data from individual mice and horizontal bars indicate the
means; stars indicate significant reduction of worm recovery compared to infected control
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p.i. (Table 3; Fig. 2). During the experiments, all mice
used (64/64) remained alive and there was not evidence
of any symptoms of severe pain, excessive distress, suf-
fering or an impending death in any of the animals.
Daily oral administration of each compound (20 mg/kg/
day) and ivermectin (0.2 mg/kg) were well tolerated by
animals in all experiments.
Discussion
To the best of our knowledge, this study represents the
first insight into therapeutic use of alkane aminoalcohols
and diamines against a nematode such as S. venezuelensis.
Synthetic new compounds developed for cancer or organ
transplantation are very attractive and untapped resources
for the development of new drugs for neglected diseases
such as the strongyloidiasis. Long chain-aminoalcohols
and diamines are sphingosine-derivatives that have been
considered as target molecules for development of new
drugs showing cytotoxicity against neoplastic cells [35],
and possessing anti-inflammatory properties [34, 36] and
ability to kill infectious agents [18, 24, 37]. However, they
have never been used against nematodes such as Strongy-
loides spp. These compounds have structural resemblances
to anticancer alkylphospholipids with anthelminthic activ-
ity against S. mansoni and S. venezuelensis [38]. Therefore,
we used the alkylphospholipid edelfosine as control for in
vitro experiments.
We have studied the structure-activity relationships in
both type I and type II compounds. We found that ami-
noalcohols 4 and 6 with a palmitoyl chain (n-hexadecan-
1-ol) and the diamines 17 and 18 with chains of lauroyl
(n-dodeca-1-ol) and palmitoyl, respectively, showed a
more potent activity against S. venezuelensis L3, with low
cytotoxicity for mammal macrophages and high selectivity
indices (SIs) indicating their potential efficacy. Concerning
aminoalcohol derivatives (compounds 1–15) the following
comparisons of results can be performed. Examination of
the substituents of the 2-amino group indicated the pref-
erence for a small- (ethyl) to medium- (butyl) sized alkyl
group in the secondary amine, as seen in derivatives 4 and
6, suggesting a decrease in the activity with increase in
substituent size increase, compound 9 activity. Interest-
ingly, compound 6 (2-n-butylamino-hexadecan-1-ol) was
found to be less toxic and had a better SI than the refer-
ence drug edelfosine. Compound 6 was also the most po-
tent and selective compound among the aminoalcohols
tested. Transformation of the secondary amines 4 and 6
into their respective tertiary analogues 11 and 13 led to a
fair reduction of activity. Regarding the 1,2-alkanedia-
mines 16–25 (Table 2), the most potent compound
against larvae was the diamine 24, a compound with a pri-
mary amine at position C-2 and a tertiary one at C-1; un-
fortunately, it showed a high cytotoxicity. Compounds 17,
18 and 23, the three Boc-protected diamines, showed
similar efficacy against L3; the last one was highly toxic,
and the other two had SIs of 1.7 and 1.4, respectively.
Compounds 17 and 18 only differed in the size of the
chain, with respective n-values of 9 and 13; in this case, a
small size chain gave less toxicity. In summary, based on
the ten alkanediamines tested, it can be concluded that
there is a preference for compounds with a Boc-protecting
group attached to the 2-amino group in the in vitro activ-
ity assays.
Inhibition of the viability of L3 induced by compound 6
increased in a dose- and time-dependent manner, demon-
strated using both XTT technique and motility records.
Lipophilic diamine and aminoalcohol derivatives contain-
ing chains with 13 carbon atoms demonstrate activity
against T. cruzi trypomastigotes [24], indicating they pos-
sess the best range of activity. It seems that the 16-carbon
chain length could be involved in the drug’s increased
solubility, absorption and harmful action, leading to the
dead of the larvae [39]. We observed that only aminoalco-
hol 6, containing an alkyl chain with a 16-carbon atom
chain and a butyl radical, displayed efficacy against S.
venezuelensis infection in mice. Although this activity was
less effective than ivermectin, the choice drug for strongyl-
oidiasis treatment, our data indicate that oral treatment
with aminoalcohol 6 significantly decreases both, the
recovered adult parthenogenetic females in the small in-
testine and the number of eggs per gram of faeces. Ami-
noalcohol 6 has also demonstrated the highest activity
against three T. cruzi strains in cultures [21].
Alkylphospholipids, aminoalcohols and diamines have
the ability to interact with membrane lipids, allowing their
penetration into the parasite where they may disturb cell
metabolism and integrity [24]. The pro-apoptotic mechan-
ism was also described in edelfosine [38, 40] and in long
chain aminoalcohols [41]. Further studies should be con-
ducted to determine the mechanisms of action. Despite
aminoalcohol 6 did not exhibit activity comparable to
ivermectin, combinations with current drugs may result in
useful synergistic interactions.
Conclusions
In conclusion, we have reported the strongyloidicidal ac-
tivity of two series of sphingosine-related compounds,
15 aminoalkanols and 10 alkanediamines, against S.
venezuelensis using L3 cultures and a strongyloidiasis
murine model to search for promising lead compounds
that can be optimized to improve their potency and se-
lectivity. This preliminary study introduces aminoalcohol
6 as a suitable prototype for the design of new anti-
Strongyloides drugs. However, further in vivo studies
need to be conducted in order to confirm the outcomes
achieved and its utility in therapy against strongyloidiasis
and other geohelminthiases.
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